Information Provided By:
Fly News Breaks for October 5, 2016
TRIB
Oct 5, 2016 | 09:08 EDT
As previously reported, Stephens analyst Drew Jones downgraded Trinity Biotech to Equal Weight from Overweight following the announcement of the withdrawal of Meritas Troponin test from FDA consideration. While the company is not abandoning the Meritas technology, the analyst notes that he currently has limited visibility into how the program will be progressed. Jones also remains conservative with expectations of Trinity Biotech successfully turning into an EPS growth story. He lowered his price target on the shares to $7 from $22.
News For TRIB From the Last 2 Days
There are no results for your query TRIB